Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 10/2023

29.08.2023 | Women and Cardiovascular Health (N Goldberg and S Lewis, Section Editors)

Challenges in Cardiovascular Imaging in Women with Breast Cancer

verfasst von: Kamari Ositelu, Alexandra Trevino, Ann Tong, Ming Hui Chen, Nausheen Akhter

Erschienen in: Current Cardiology Reports | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Cardiovascular imaging in breast cancer patients is paramount for the surveillance of cancer therapy-related cardiac dysfunction (CTRCD); however, it comes with specific limitations.

Purpose of Review

This review aims to describe the unique challenges faced in cardiovascular imaging of breast cancer patients, discuss evidence to support the utility of various imaging modalities, and provide solutions for improvement in imaging this unique population.

Recent Findings

Updated clinical society guidelines have introduced more unifying surveillance of CTRCD, although there remains a lack of a universally accepted definition. Traditional and novel multi-modality imaging can be used to detect CTRCD and myocarditis in breast cancer patients.

Summary

Cardiovascular imaging in breast cancer patients is difficult due to reconstructive surgery. Although echocardiography with myocardial strain is the cornerstone, multi-modality imaging can be used to evaluate for CTRCD and myocarditis. Novel imaging techniques to improve the diagnosis of cardiotoxicities in breast cancer patients are needed.
Literatur
1.
Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–41.PubMedCrossRef
2.
Abdel-Qadir H, Austin PC, Lee DS, Amir E, Tu JV, Thavendiranathan P, et al. A population-based study of cardiovascular mortality following early-stage breast cancer. JAMA Cardiol. 2017;2(1):88–93.PubMedCrossRef
3.
4.
Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation. 2022;145(8):e153–639.PubMedCrossRef
5.
Montisci A, Vietri MT, Palmieri V, Sala S, Donatelli F, Napoli C. Cardiac toxicity associated with cancer immunotherapy and biological drugs. Cancers (Basel). 2021;13(19).
6.
Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60(24):2504–12.PubMedCrossRef
7.
Florescu M, Cinteza M, Vinereanu D. Chemotherapy-induced cardiotoxicity. Maedica (Bucur). 2013;8(1):59–67.PubMed
8.
Jiji RS, Kramer CM, Salerno M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol. 2012;19(2):377–88.PubMedPubMedCentralCrossRef
9.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.PubMedCrossRef
10.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.PubMedCrossRef
11.
Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457–67.PubMedCrossRef
12.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556–67.PubMedCrossRef
13.
Oren O, Blankstein R, Bhatt DL. Addressing imaging pitfalls to reduce cardiovascular disease misdiagnosis in patients with breast cancer following reconstruction. JAMA Cardiol. 2022;7(2):123–5.PubMedCrossRef
14.
Pignatti M, Mantovani F, Bertelli L, Barbieri A, Pacchioni L, Loschi P, et al. Effects of silicone expanders and implants on echocardiographic image quality after breast reconstruction. Plast Reconstr Surg. 2013;132(2):271–8.PubMedCrossRef
15.
Schwartz RG, McKenzie WB, Alexander J, Sager P, D'Souza A, Manatunga A, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82(6):1109–18.
16.
Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–21.PubMedCrossRef
17.
Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063–93.PubMedPubMedCentralCrossRef
18.
•• Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361. The ESC guideline written in collaboration with other clinical societies serves as the most contemporary and comphrensive guide for the diagnosis, management, and surivellance of CTRCD at the time of the current review article.
19.
Stone JR, Kanneganti R, Abbasi M, Akhtari M. Monitoring for chemotherapy-related cardiotoxicity in the form of left ventricular systolic dysfunction: a review of current recommendations. JCO Oncol Pract. 2021;17(5):228–36.PubMedCrossRef
20.
Horacek JM, Jakl M, Horackova J, Pudil R, Jebavy L, Maly J. Assessment of anthracycline-induced cardiotoxicity with electrocardiography. Exp Oncol. 2009;31(2):115–7.PubMed
21.
Yu C, Pathan F, Tan TC, Negishi K. The Utility of advanced cardiovascular imaging in cancer patients-When, why, how, and the latest developments. Front Cardiovasc Med. 2021;8: 728215.PubMedPubMedCentralCrossRef
22.
Fraser AG, Monaghan MJ, van der Steen AFW, Sutherland GR. A concise history of echocardiography: timeline, pioneers, and landmark publications. Eur Heart J Cardiovasc Imaging. 2022;23(9):1130–43.PubMedPubMedCentralCrossRef
23.
24.
Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63(25 Pt A):2751–68.
25.
Rosmini S, Aggarwal A, Chen DH, Conibear J, Davies CL, Dey AK, et al. Cardiac computed tomography in cardio-oncology: an update on recent clinical applications. Eur Heart J Cardiovasc Imaging. 2021;22(4):397–405.PubMedPubMedCentralCrossRef
26.
Mitra D, Basu S. Equilibrium radionuclide angiocardiography: its usefulness in current practice and potential future applications. World J Radiol. 2012;4(10):421–30.PubMedPubMedCentralCrossRef
27.
D’Amore C, Gargiulo P, Paolillo S, Pellegrino AM, Formisano T, Mariniello A, et al. Nuclear imaging in detection and monitoring of cardiotoxicity. World J Radiol. 2014;6(7):486–92.PubMedPubMedCentralCrossRef
28.
Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002;86(11):1697–700.PubMedPubMedCentralCrossRef
29.
Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–79.PubMedCrossRef
30.
Makis W. MUGA image artefacts caused by metallic injection ports in breast reconstruction tissue expanders: a report of two breast cancer patients. BJR Case Rep. 2016;2(3):20150421.PubMedPubMedCentral
31.
Pinamonti B, Abate E, De Luca A, Finocchiaro G, Korcova R. Role of Cardiac Imaging: Echocardiography. In: Sinagra G, Merlo M, Pinamonti B, editors. Dilated Cardiomyopathy: From Genetics to Clinical Management. Cham (CH): Springer Copyright 2019, The Author(s). 2019. p. 83–111.
32.
Esmaeilzadeh M, Urzua Fresno CM, Somerset E, Shalmon T, Amir E, Fan CS, et al. A combined echocardiography approach for the diagnosis of cancer therapy-related cardiac dysfunction in women with early-stage breast cancer. JAMA Cardiol. 2022;7(3):330–40.PubMedPubMedCentralCrossRef
33.
McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J. 1983;106(5 Pt 1):1048–56.PubMedCrossRef
34.
Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61(1):77–84.PubMedCrossRef
35.
36.
Larsson MK, Da Silva C, Gunyeli E, Ilami AA, Szummer K, Winter R, et al. The potential clinical value of contrast-enhanced echocardiography beyond current recommendations. Cardiovasc Ultrasound. 2016;14:2.PubMedPubMedCentralCrossRef
37.
Liang S, Liu M, Liu Z, Zhong X, Qin Y, Liang T, et al. Global longitudinal strain assessment in contrast-enhanced echocardiography in breast cancer patients: a feasibility study. Cardiovasc Ultrasound. 2023;21(1):7.PubMedPubMedCentralCrossRef
38.
Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol. 2011;57(22):2263–70.PubMedCrossRef
39.
Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596–603.PubMedPubMedCentralCrossRef
40.
Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375–80.PubMedPubMedCentralCrossRef
41.
Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013;26(5):493–8.PubMedCrossRef
42.
Ye L, Yang ZG, Selvanayagam JB, Luo H, Yang TZ, Perry R, et al. Myocardial strain imaging by echocardiography for the prediction of cardiotoxicity in chemotherapy-treated patients: a meta-analysis. JACC Cardiovasc Imaging. 2020;13(3):881–2.PubMedCrossRef
43.
• Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S, et al. Cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy: 3-year results of the SUCCOUR trial. JACC Cardiovasc Imaging. 2023;16(3):269–78. This randomized clinical trial compared the utility of GLS vs. LVEF surveillance in monitoring CTRCD. The trial showed that a GLS-based strategy for the detection and treatment of CTRCD was not superior to an LVEF-based strategy.
44.
Lightfoot JC, D’Agostino RB Jr, Hamilton CA, Jordan J, Torti FM, Kock ND, et al. Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circ Cardiovasc Imaging. 2010;3(5):550–8.PubMedPubMedCentralCrossRef
45.
Tahir E, Azar M, Shihada S, Seiffert K, Goy Y, Beitzen-Heineke A, et al. Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT. Eur Radiol. 2022;32(3):1853–65.PubMedCrossRef
46.
Burrage MK, Ferreira VM. The use of cardiovascular magnetic resonance as an early non-invasive biomarker for cardiotoxicity in cardio-oncology. Cardiovasc Diagn Ther. 2020;10(3):610–24.PubMedPubMedCentralCrossRef
47.
Giusca S, Korosoglou G, Montenbruck M, Geršak B, Schwarz AK, Esch S, et al. Multiparametric early detection and prediction of cardiotoxicity using myocardial strain, T1 and T2 mapping, and biochemical markers: a longitudinal cardiac resonance imaging study during 2 years of follow-up. Circ Cardiovasc Imaging. 2021;14(6): e012459.PubMedPubMedCentralCrossRef
48.
Marano AA, Henderson PW, Prince MR, Dashnaw SM, Rohde CH. Effect of MRI on breast tissue expanders and recommendations for safe use. J Plast Reconstr Aesthet Surg. 2017;70(12):1702–7.PubMedCrossRef
49.
Woolen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS. Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis. JAMA Intern Med. 2020;180(2):223–30.PubMedCrossRef
50.
Feher A, Baldassarre LA, Sinusas AJ. Novel cardiac computed tomography methods for the assessment of anthracycline induced cardiotoxicity. Front Cardiovasc Med. 2022;9: 875150.PubMedPubMedCentralCrossRef
51.
Egashira K, Sueta D, Tomiguchi M, Kidoh M, Oda S, Usuku H, et al. Cardiac computed tomography-derived extracellular volume fraction in late anthracycline-induced cardiotoxicity. Int J Cardiol Heart Vasc. 2021;34: 100797.PubMedPubMedCentral
52.
Wang R, Fang Z, Wang H, Schoepf UJ, Emrich T, Giovagnoli D, et al. Quantitative analysis of three-dimensional left ventricular global strain using coronary computed tomography angiography in patients with heart failure: comparison with 3T cardiac MR. Eur J Radiol. 2021;135: 109485.PubMedCrossRef
53.
Chadashvili T, Litmanovich D, Hall F, Slanetz PJ. Do breast arterial calcifications on mammography predict elevated risk of coronary artery disease? Eur J Radiol. 2016;85(6):1121–4.PubMedCrossRef
54.
Yoon YE, Kim KM, Han JS, Kang SH, Chun EJ, Ahn S, et al. Prediction of subclinical coronary artery disease with breast arterial calcification and low bone mass in asymptomatic women: Registry for the Women Health Cohort for the BBC Study. JACC Cardiovasc Imaging. 2019;12(7 Pt 1):1202–11.PubMedCrossRef
55.
Chuzi S, Rangarajan V, Jafari L, Vaitenas I, Akhter N. Subcostal view-based longitudinal strain in patients with breast cancer is an alternative to conventional apical view-based longitudinal strain. J Am Soc Echocardiogr. 2019;32(4):514-20.e1.PubMedCrossRef
56.
Zhao R, Shu F, Zhang C, Song F, Xu Y, Guo Y, et al. Early detection and prediction of anthracycline-induced right ventricular cardiotoxicity by 3-dimensional echocardiography. JACC CardioOncol. 2020;2(1):13–22.PubMedPubMedCentralCrossRef
57.
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801.PubMedCrossRef
58.
Timóteo AT, Moura Branco L, Filipe F, Galrinho A, Rio P, Portugal G, et al. Cardiotoxicity in breast cancer treatment: what about left ventricular diastolic function and left atrial function? Echocardiography. 2019;36(10):1806–13.PubMedCrossRef
59.
Chen N, Liu A, Sun S, Wei H, Sun Q, Shang Z, et al. Evaluation of left atrial function and mechanical dispersion in breast cancer patients after chemotherapy. Clin Cardiol. 2022;45(5):540–8.PubMedPubMedCentralCrossRef
60.
Hinrichs L, Mrotzek SM, Mincu RI, Pohl J, Röll A, Michel L, et al. Troponins and natriuretic peptides in cardio-oncology patients-data from the ECoR Registry. Front Pharmacol. 2020;11:740.PubMedPubMedCentralCrossRef
61.
de Korte MA, de Vries EG, Lub-de Hooge MN, Jager PL, Gietema JA, van der Graaf WT, et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer. 2007;43(14):2046–51.PubMedCrossRef
62.
Schwartz RG, Jain D, Storozynsky E. Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively. J Nucl Cardiol. 2013;20(3):443–64.PubMedCrossRef
63.
Hong YJ, Kim GM, Han K, Kim PK, Lee SA, An E, et al. Cardiotoxicity evaluation using magnetic resonance imaging in breast Cancer patients (CareBest): study protocol for a prospective trial. BMC Cardiovasc Disord. 2020;20(1):264.PubMedPubMedCentralCrossRef
64.
Chen H, Ouyang D, Baykaner T, Jamal F, Cheng P, Rhee JW. Artificial intelligence applications in cardio-oncology: leveraging high dimensional cardiovascular data. Front Cardiovasc Med. 2022;9: 941148.PubMedPubMedCentralCrossRef
65.
Salte IM, Østvik A, Smistad E, Melichova D, Nguyen TM, Karlsen S, et al. Artificial intelligence for automatic measurement of left ventricular strain in echocardiography. JACC Cardiovasc Imaging. 2021;14(10):1918–28.PubMedCrossRef
66.
Baratta SDM, Marchese M, Trucco J, Rizzo M, Bernok F. Serum markers, conventional Doppler echocardiography and two-dimensional systolic strain in the diagnosis of chemotherapy-induced myocardial toxicity. Rev Argent Cardiol. 2013;81(2):151–8.
Metadaten
Titel
Challenges in Cardiovascular Imaging in Women with Breast Cancer
verfasst von
Kamari Ositelu
Alexandra Trevino
Ann Tong
Ming Hui Chen
Nausheen Akhter
Publikationsdatum
29.08.2023
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 10/2023
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-01941-3

Weitere Artikel der Ausgabe 10/2023

Current Cardiology Reports 10/2023 Zur Ausgabe

Diversity and Health Equity in Cardiology (AE Johnson, Section Editor)

Exploring Nursing Strategies to Engage Community in Cardiovascular Care

Psychological Aspects of Cardiovascular Diseases (IM Kronish, Section Editor)

Screening for Emotional Distress in Patients with Cardiovascular Disease

Pericardial Disease (AL Klein and CL Jellis, Section Editors)

Radiation-Induced Pericardial Disease: Mechanisms, Diagnosis, and Treatment

Hypertension (DS Geller and DL Cohen, Section Editors)

The Promise and Illusion of Continuous, Cuffless Blood Pressure Monitoring

Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)

Arterial Stiffness and its Impact on Cardiovascular Health

Lipid Abnormalities and Cardiovascular Prevention (ED Michos, Section Editor)

Is Lipoprotein(a) Clinically Actionable with Today’s Evidence? The Answer is Yes

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen